Search the Newsreel

Cellectis (NASDAQ:CLLS) Releases Earnings Results, Beats Estimates By $0.04 EPS

Barclays Initiates Cellectis(CLLS.US) With Buy Rating, Announces Target Price $9

Barclays has initiated coverage of Cellectis (CLLS.US) with a Buy rating. The firm has set a price target of $9 for the company's stock.

Cellectis Reports Financial Results for the Second Quarter 2026

Cellectis, a clinical-stage biotechnology company, reported its financial results for the second quarter of 2026

Cellectis earnings beat by $0.04, revenue fell short of estimates

Cellectis (NASDAQ: CLLS) reported Q2 EPS of $-0.220, beating analyst estimates by $0.04, but revenue of $6.9M fell short of the $10.97M consensus. The company's stock is down 30.130% in the last three months but up 1.130% over the last year. The article also …

Cellectis Q2: $169M Cash, FDA RMAT for Lasme-cel | CLLS Stock News

Cellectis reported its Q2 2026 financial results, highlighting $169 million in cash, cash equivalents, and fixed-term deposits, providing a runway into Q4 2027. The company announced that its investigational therapy, lasme-cel, received FDA RMAT designation for relapsed or refractory B-ALL based on Phase 1 …

Cellectis Reports 105.6M Voting Rights as of July 31

Cellectis (CLLS) has disclosed its monthly share capital and voting rights as of July 31, 2026, reporting 100,701,207 shares outstanding and 105,554,794 voting rights. This disclosure is in accordance with Article 223-16 of the French financial markets authority. The company's shares are listed on …

Cellectis (NASDAQ: CLLS) reports H1 2026 loss but $169M cash runway

Cellectis (NASDAQ: CLLS) posts $39.6M H1 loss, holds $166.8M cash

CLLS|Cellectis SA|Price:2.920|Chg%:+0.170

This article provides a comprehensive stock analysis of Cellectis SA (CLLS) by TradingKey, detailing its financial health, valuation, growth potential, and institutional confidence. The company is described as a France-based genome engineering firm with significant revenue growth and a "Buy" analyst rating despite a …

Cellectis (CLLS) to Post Quarterly Earnings on Thursday

Cellectis (CLLS) is scheduled to report its H1 2026 earnings after market close on Thursday, August 6th, with analysts forecasting a loss of $0.263 per share and revenue of $11.05 million. The biotechnology company previously reported an EPS loss of $0.18, beating estimates, but …

Cellectis SA expected to post a loss of 26 cents a share - Earnings Preview

Cellectis SA is projected to report a loss of 26 cents per share, according to an earnings preview. This forecast comes from Refinitiv and is being highlighted by TradingView News.

Cellectis Q2 Results: Financials due August 6 after close

Cellectis (NASDAQ: CLLS) will report its Q2 2026 financial results on August 6, 2026, after the close of the US market. The company will not host a conference call to discuss these results, instead making the details available on its investor relations website and …

Cellectis (NASDAQ: CLLS) sets August 6 date for Q2 2026 results

Cellectis (NASDAQ: CLLS), a clinical-stage biotechnology company, announced it would release its second-quarter 2026 financial results on Thursday, August 6, 2026, after the close of the US market. The company specified that it would not host a conference call for these results but would …

Cellectis Q2 Results Set for Aug. 6; No Call Planned

Cellectis (CLLS) will report its second-quarter 2026 financial results on August 6, 2026, after the U.S. market closes. The company will not host a conference call to discuss these results but will make the press release available on its investor website. Investors can direct …

Cellectis to report second-quarter results after US market close

Cellectis announced it will release its second-quarter 2026 financial results on August 6, 2026, after the close of U.S. trading. The results will be posted in the investor relations press releases section of their website. This news brief was generated by Public Technologies using …

Cellectis to Report Second Quarter Financial Results on August 6, 2026

Cellectis (CLLS), a clinical-stage biotechnology company, announced it will report its second quarter 2026 financial results on Thursday, August 6, 2026, after the close of the US market. The results will be accessible via a press release on the Investors section of their website. …

Cellectis SA (CLLS) Technical Analysis: Support, Resistance, Indicators & Moving Averages

This article provides a technical analysis of Cellectis SA (CLLS), detailing its price momentum score of 4.63 and noting its current trading range between a resistance level of $3.30 and a support level of $2.50. It presents a summary of various technical indicators like …

Cellectis Romainville Revenue Breakdown – OTC:CMVLF

Cellectis Romainville (CMVLF) reported total revenue of $79.67 million USD last year. The Therapeutics segment was the top-performing segment, generating $75.92 million USD, a significant increase from the previous year. The majority of this revenue, $75.92 million USD, originated from France.

CLLS|Cellectis SA|Price:2.840|

This article provides a detailed company profile for Cellectis SA (CLLS), a France-based genome engineering and genomic surgery company specializing in immunotherapies for cancer. It covers the company's background, business scope, financial data, market performance, key executives, and institutional shareholdings. Cellectis SA focuses on …

Cellectis SA (CLLS) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Cellectis SA (CLLS), focusing on business segments and regional revenue contributions. However, it notes that relevant data from the company for FY2025, FY2024, FY2023, FY2022, FY2021, FY2020, FY2019, and FY2018 have not yet been disclosed. The only …

Cellectis SA (CLLS) Valuation: PE, PB & Fair Value Analysis

The article provides a valuation analysis for Cellectis SA (CLLS), noting its current valuation score of 7.78, ranking 194th in the Biotechnology & Medical Research industry. It highlights the company's P/E ratio of -4.31, which is significantly below its recent high but above its …

Cellectis SA (CLLS) Risk Assessment: Volatility, Financial Risk & Investment Risk

This article provides a detailed risk assessment for Cellectis SA (CLLS), focusing on volatility, financial risk, and investment risk. It presents various metrics such as Beta, VaR, Maximum Drawdown, Volatility, Sharpe Ratio, Skewness, and Liquidity. The data covers different timeframes, offering insights into the …

Cellectis S.A. Revenue Breakdown – EURONEXT:ALCLS

This article details Cellectis S.A.'s revenue breakdown for the last year, showing the company generated €67.83 million. The Therapeutics segment was the top performer, contributing €64.64 million, primarily from France.

Cellectis S.A. Sponsored ADR Revenue Breakdown – LS:A14QZE

Cellectis S.A. Sponsored ADR (A14QZE) generated 67.77 million EUR in revenue last year. The Therapeutics segment was the top-performing segment, contributing 62.11 million EUR, an increase from 40.09 million EUR the previous year. France was the largest geographical contributor, matching the Therapeutics segment's revenue.

CLLS|Cellectis SA|Price:2.840|Chg%:+0.070

This article provides a detailed financial overview and analysis of Cellectis SA (CLLS). It highlights the company's fundamentals, growth potential, valuation, and analyst ratings, indicating a "Buy" consensus with a significant upside. The report also includes key figures, stock performance across various periods, and …

Cellectis S.A. (NASDAQ:CLLS) Receives Average Recommendation of "Moderate Buy" from Brokerages

Cellectis S.A. (NASDAQ:CLLS) has received an average "Moderate Buy" recommendation from six analysts, with a consensus price target of $7.00. While some analysts have initiated or reiterated "buy" ratings with higher price targets, one analyst maintained a "sell" rating. The company recently beat quarterly …

ETFs Investing in Cellectis S.A. Sponsored ADR Stocks

This article lists ETFs that include Cellectis S.A. Sponsored ADR stocks. It highlights the iShares Biotechnology ETF (IBB) as one such fund, providing its market value, weight, issuer, expense ratio, AUM, price, change, related volume, and 3-year NAV total return. The information aims to …